

ACE Immunoid™

Next-generation sequencing platform for clinical trials

Many patients do not show sustained response to immunotherapy.

However, new research suggests that biomarkers such as mutational burden and neoantigen load may be accurate predictors of patient response and may be associated with:



More **tumor-infiltrating lymphocytes**



Durable response to immunotherapy



Improved patient survival


Developing the immunotherapies of tomorrow takes a new approach.

Personalis offers a one-stop solution for biomarker implementation with analytically validated next-generation sequencing (NGS) assays:

ACE Immunoid:

- ACE Cancer Exome™
- ACE Cancer Transcriptome™
- ACE Extended Cancer Panel for DNA & RNA™

- Mutational burden
- Neoantigen detection
- Immune checkpoint/modulator ligand expression
- Tumor profiling



Backed by an experienced genomics partner.



>10,000
Exomes sequenced
And >2,000 whole genomes



>60
Partnerships
with research centers and biopharma in 16 countries



CAP accredited
CLIA certified
GCP compliant
Genomics laboratory

Together, we can transform the future of cancer care.

To learn more, contact us at info@personalis.com